Significantly mutated gene (SMG) clusters for each conventional RCC subtype have also been defined, with RCC signature mutations (in VHL and PBRM1), alongside other non-specific mutations in SETD2, KDM5C, PTEN, BAP1, MTOR, and TP53 [64], being the most relevant in predicting RCC outcomes. The gene discussed is BAP1; the disease is renal cell carcinoma.